Eprenetapopt (APR-246) and Azacitidine in TP53-Mutant Myelodysplastic Syndromes

Approximately 20% of patients with TP53-mutant myelodysplastic syndromes (MDS) achieve complete remission (CR) with hypomethylating agents. Eprenetapopt (APR-246) is a novel, first-in-class, small molecule that restores wild-type p53 functions in TP53-mutant cells. METHODS: This was a phase Ib/II st...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Clin Oncol
Main Authors: Sallman, David A., DeZern, Amy E., Garcia-Manero, Guillermo, Steensma, David P., Roboz, Gail J., Sekeres, Mikkael A., Cluzeau, Thomas, Sweet, Kendra L., McLemore, Amy, McGraw, Kathy L., Puskas, John, Zhang, Ling, Yao, Jiqiang, Mo, Qianxing, Nardelli, Lisa, Al Ali, Najla H., Padron, Eric, Korbel, Greg, Attar, Eyal C., Kantarjian, Hagop M., Lancet, Jeffrey E., Fenaux, Pierre, List, Alan F., Komrokji, Rami S.
Formato: Artigo
Idioma:Inglês
Publicado em: Wolters Kluwer Health 2021
Assuntos:
ORIGINAL REPORTS
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8099410/
https://ncbi.nlm.nih.gov/pubmed/33449813
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.20.02341
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados